Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ardent Health (ARDT) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Ardent Health (ARDT) over the last 3 years, with Q3 2025 value amounting to $609.4 million.

  • Ardent Health's Cash & Equivalents rose 822.15% to $609.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $609.4 million, marking a year-over-year increase of 822.15%. This contributed to the annual value of $556.8 million for FY2024, which is 2724.27% up from last year.
  • Ardent Health's Cash & Equivalents amounted to $609.4 million in Q3 2025, which was up 822.15% from $540.6 million recorded in Q2 2025.
  • Ardent Health's Cash & Equivalents' 5-year high stood at $609.4 million during Q3 2025, with a 5-year trough of $334.5 million in Q2 2024.
  • In the last 3 years, Ardent Health's Cash & Equivalents had a median value of $540.6 million in 2025 and averaged $505.3 million.
  • Data for Ardent Health's Cash & Equivalents shows a peak YoY increase of 6160.47% (in 2025) and a maximum YoY decrease of 822.15% (in 2025) over the last 5 years.
  • Over the past 3 years, Ardent Health's Cash & Equivalents (Quarter) stood at $437.6 million in 2023, then grew by 27.24% to $556.8 million in 2024, then grew by 9.46% to $609.4 million in 2025.
  • Its Cash & Equivalents was $609.4 million in Q3 2025, compared to $540.6 million in Q2 2025 and $495.0 million in Q1 2025.